Who is sponsoring NCT04606953?

NCT04606953 is sponsored by University of Paris 5 - Rene Descartes.

What drugs are being tested in NCT04606953?

Interventions in NCT04606953: Attention Process Training (APT-II).

What condition does NCT04606953 study?

NCT04606953 studies Mild Cognitive Impairment, Alzheimer Disease.

Is NCT04606953 still recruiting?

NCT04606953 is currently completed. Last updated 29 September 2021.

Last reviewed 2021-09-29 · How we verify

NCT04606953: APT-II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Working Memory Training in Older Adults With Mild Cognitive Impairment : Impacts on Cognition and Ecological Activities

Completed NA Last updated 29 September 2021

What this trial tests

NA trial testing Attention Process Training (APT-II) in Mild Cognitive Impairment in 24 participants. Completed in 27 September 2021.

Timeline

1 February 2019

Primary endpoint
30 July 2021

27 September 2021

Quick facts

Lead sponsor	University of Paris 5 - Rene Descartes
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	24
Start date	1 February 2019
Primary completion	30 July 2021
Estimated completion	27 September 2021
Sites	1 location across France

Drugs / interventions tested

Attention Process Training (APT-II)

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

University of Paris 5 - Rene Descartes

Who can join

55 and older, any sex, with Mild Cognitive Impairment or Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Older adults with Mild Cognitive Impairment (MCI) have an increased risk of developing dementia but do not meet the criteria for dementia. Cognitive rehabilitation makes it possible to compensate, at least in part, for cognitive deficits with the ultimate goal of reducing their impact in everyday life. The objective of the research is to evaluate the short- and long-term effectiveness and generalization of an attention and working memory training program (APT-II) on cognition and ecological activities in MCI patients with a randomized controlled trial. Thirty MCI patients will be randomly assigned between a "cognitive training with APT-II" condition and a control (routine care) condition. The intervention will consist of an 8-week individual cognitive training program (2 sessions/week), training different attentional components and working memory. This has the advantage of insisting on the transfer of the acquired knowledge in sessions to daily activities. To evaluate the effectiveness of the treatment, cognitive and functional follow-up measures (including a virtual reality task) are administered at several time intervals. This project should contribute to better management of cognitive disorders by offering a new standardized rehabilitation tool in French to clinical practice.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Effect of Attention Process Training (APT-II) On Cognitive and Daily Life Functioning in Patients With a Mild Cognitive Impairment: A Randomized Controlled Trial
Saba M, Rwabihama J, Bouvard É, Mettling P, et al · · 2021 · DOI 10.21203/rs.3.rs-861371/v1

Verify or expand the search:

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other University of Paris 5 - Rene Descartes trials

Trials by the same sponsor.

NCT03697772 — Continuity of Care and Use of Urgent Healthcare in Multimorbid Patients · completed
NCT03785483 — Implementation Intention for Physical Activity in Multiple Sclerosis · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04606953 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Paris 5 - Rene Descartes
Last refreshed: 29 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04606953.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing